MLTX MoonLake Immunotherapeutics Class A Ordinary Shares
XNAS
12.71
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MLTX
$12.71
—
What changed
Recent filings, trades and movesKey stats
$12.71
- 52-Week Range
- $9.46 – $23.29
- YTD
- +6.40%
- IV Rank (30D)
- 39.55
- Straddle Price
- $3.22
- P/C Vol Ratio
- 0.46
- Market Cap
- $1.0B
- Open
- $11.82
- Day Range
- $11.59 – $12.85
- Volume
- 963,044
- Prev Close
- $11.53
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.90 |
| Cost of Equity (CAPM) | 9.41% (VRP-adj) |
| WACC | 8.99% |
| Volatility Risk Premium | +50.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -61.2% |
| Book / Price | 50.2% — banking bias active (P/B is primary) |
| Debt / Equity | 0.23 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $12.11 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $11.17 |
| Bollinger Width / SMA20 | 31.6% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $1B |
Peers used for multiples: DYN, IMNM, UNH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
69%
20-Day Fair Value
≈ by Dec 8, 2026
$12.75
α +0.4%
rank 50%
conviction
27%
40-Day Fair Value
≈ by Jan 6, 2027
$13.11
α +3.2%
rank 58%
conviction
82%
60-Day Fair Value
≈ by Feb 4, 2027
$13.09
α +3.0%
rank 59%
conviction
69%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $23.29 | 16% | median 4.0× · 3 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $12.11 | 57% | stability 68% (BB-width) |
| Options Expected (B-L 30d) | $10.98 | 27% | 13 strikes · skew +0.38 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.0B
- Employees
- 130
- List Date
- 2022-04-06
- CIK
- 0001821586
- Last Earnings
- Nov 4 before open · −1.2% vs ±16.9% expected
- Next Earnings
- ~Feb 22, 2027 (estimated)
- Headquarters
- Zug, V8
- Homepage
- https://www.moonlaketx.com
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 8.39% | -6.16% | -14.15% | 31.13% | 4.80% |
| Feb | -- | 57.17% | -15.40% | -4.33% | 10.89% | 12.08% |
| Mar | -- | 6.95% | -1.36% | -1.61% | 5.43% | 2.35% |
| Apr | -49.39% | 3.30% | -15.82% | 15.76% | -0.85% | -9.40% |
| May | 31.02% | 19.87% | -5.09% | -5.86% | 14.64% | 10.92% |
| Jun | -30.00% | 85.12% | 4.72% | 14.67% | 3.45% | 15.59% |
| Jul | 12.20% | 19.94% | -0.36% | 8.22% | -3.58% | 7.28% |
| Aug | 15.14% | -0.48% | 11.27% | 5.35% | -13.51% | 3.55% |
| Sep | -7.07% | 5.69% | 8.87% | -87.76% | -22.67% | -20.59% |
| Oct | 3.65% | -10.02% | -10.25% | 43.06% | 2.70% | 5.83% |
| Nov | 24.12% | -9.58% | 16.40% | 34.61% | 10.55%* | 15.22% |
| Dec | 5.00% | 31.00% | -2.38% | -0.53% | -- | 8.27% |
| Total | -24.73% | 461.56% | -19.35% | -73.01% | 31.99% | 75.29% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $11.27
SMA 50: $12.06
SMA 200: $16.33
Current: $12.71
EMA 12: $11.67
EMA 26: $11.68
MACD: -0.0096 | Signal: 0.1543
BEARISH
ADX (14): 26.12
TREND
+DI: 31.28
−DI: 20.67
Momentum Oscillators
RSI (14): 58.27
NEUTRAL
Stoch %K: 54.28
Stoch %D: 49.65
Williams %R: -21.01
Volume & Volatility
BB Upper: $13.14
BB Lower: $9.40
NEUTRAL
OBV: 32,959,926
Vol SMA 20: 1,662,500
Vol ROC: -36.82%
ATR: $0.80
True Range: $1.32
HV 20: 88.0%
HV 30: 74.2%
HV 60: 63.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before MLTX’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers: Negative news sentiment, bearish momentum signals, low volatility.
Primary Risks: Earnings miss, regulatory issues, and potential further price decline.
Recent News Sentiment Impact: Negative headline from Robbins Geller Rudman & Dowd LLP announcing a potential class action lawsuit against MLTX. This negative news could contribute to the stock's downtrend.
Technical Analysis
Trend Direction: Downtrend (Short-term: 1-4 weeks, Medium-term: 1-3 months)
Support/Resistance Levels:
- SMA 20 ($20.60) as a potential support level
- Lower Bollinger Band (-$20.42) as a potential resistance level
Momentum Signals:
- RSI (14): 24.34 (oversold)
- Interpretation: Potential buy signal, but overall momentum remains bearish
- MACD: -10.48 / Signal: 0.42 / Histogram: -10.90 (bearish)
- Interpretation: Bearish momentum signal
Volume Analysis: Low volume and a downward trend in the On-Balance Volume (OBV) indicate market selling pressure.
News & Sentiment Analysis
Recent Headlines Summary: Negative news headlines regarding potential lawsuits and regulatory issues.
Sentiment Assessment: NEGATIVE
Catalyst Identification: Upcoming earnings release on 2025-11-18. Potential for further price decline if earnings miss expectations.
Market Narrative: The negative sentiment surrounding MLTX's potential class action lawsuit could continue to drive the stock lower.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta = 0.74).
Volatility Regime: Low volatility compared to historical levels.
Options Market Signals:
- IV Rank: 27.6% (Medium) indicating moderate volatility
- Put/Call Volume Ratio: 0.15 (Bullish sentiment)
- Options market pricing a $2.62 move by expiration
Market Context & Positioning
Sector Performance: Weak sector performance, which could contribute to the stock's decline.
Institutional Activity: Low institutional interest and buying pressure.
Correlation Analysis: The stock has shown negative correlation with the market (R-squared = 0.14).
Relative Valuation: Underperforming relative to its peers and sector.
Key Levels & Action Items
Critical Price Levels:
- Support at SMA 20 ($20.60)
- Resistance at Lower Bollinger Band (-$20.42)
Breakout/Breakdown Levels:
- Break above Lower Bollinger Band (-$20.42) could trigger a buy signal
- Break below SMA 20 ($20.60) could trigger further selling pressure
Time-Sensitive Catalysts: Upcoming earnings release on 2025-11-18.
Risk Management: Consider setting stop-loss levels at $10.50 or lower to manage potential losses.
Note: This analysis is based on the provided data and should not be considered as personalized investment advice.
Generated
News
All MLTX news →
Earnings History
14 of 14 under expected move
Avg Expected Move
12.51%
Avg Actual Move
3.23%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-08-10 | Pre-Market | 11.25% | 0.55% | 0.05x | Within |
| 2023-11-14 | Pre-Market | 9.54% | 1.99% | 0.21x | Within |
| 2024-02-29 | Pre-Market | 18.57% | 15.09% | 0.81x | Within |
| 2024-05-07 | Pre-Market | 11.34% | 1.93% | 0.17x | Within |
| 2024-08-07 | Pre-Market | 10.98% | 1.98% | 0.18x | Within |
| 2024-11-07 | Pre-Market | 10.10% | 1.57% | 0.16x | Within |
| 2025-02-26 | Pre-Market | 12.77% | 4.03% | 0.32x | Within |
| 2025-05-12 | Pre-Market | 6.89% | 4.45% | 0.65x | Within |
| 2025-08-05 | Pre-Market | 8.96% | 0.17% | 0.02x | Within |
| 2025-11-05 | Pre-Market | 15.30% | 4.54% | 0.30x | Within |
| 2026-02-23 | Pre-Market | 22.51% | 0.48% | 0.02x | Within |
| 2026-05-11 | After-Close | 7.30% | 3.45% | 0.47x | Within |
| 2026-08-11 | After-Close | 12.81% | 3.86% | 0.30x | Within |
| 2026-11-04 | Pre-Market | 16.88% | 1.20% | 0.07x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MLTX Options Activity & IV Rank
MLTX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 95.0%
7-DTE IV: 76.2%
Expected Move: $3.22
7-DTE Move: $1.35
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 2,075
Put Volume: 951
P/C Volume: 0.458
BULLISH
Call OI: 34,558
Put OI: 6,350
P/C OI: 0.184
Total OI: 40,908
ATM Options Pricing
ATM Call: $1.57
ATM Put: $1.65
Call %: 12.4%
Put %: 13.0%
Chain Summary
Chain Volume: 3,026
Chain OI: 40,908
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 31st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
31%
vs own history
GEX tilt
+0.22
OI-weighted, today
Vanna tilt
+0.71
δ-sensitivity to IV
Charm tilt
-0.79
δ-decay vs time
Vanna tilt +0.71: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.79: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 20 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)16.8LowNov 9
IV Rank (30 DTE)39.5MediumNov 9
Straddle Price (30 DTE)$3.22Nov 9
Beta Analysis
Risk Metrics
Beta: 1.5026
Alpha: 24.96%
Correlation: 0.2776
R-Squared: 7.7%
Stock Volatility: 74.6%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MLTX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $38.4M | #820 of 6285 | +49.0% | 13F | |
| Point72 Hedge fund Steve Cohen | $22.6M | #556 of 1945 | -15.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $12.5M | #928 of 3138 | +132.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $12.4M | #1435 of 3716 | +10.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MLTX Institutional Ownership (13F)
Filings for 2026-06-30 · 41 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 69,131,996 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
12 filers$32.79M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $6.36M | 19.41% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $6.25M | 19.06% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $5.33M | 16.27% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $5.32M | 16.22% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $3.56M | 10.87% | 2026-06-30 |
| 6 | Centiva Capital, LP | $1.95M | 5.94% | 2026-06-30 |
| 7 | J. Goldman & Co LP | $1.95M | 5.94% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $717.21K | 2.19% | 2026-09-30 |
| 9 | Simplex Trading, LLC Custodian | $642.33K | 1.96% | 2026-09-30 |
| 10 | TUDOR INVESTMENT CORP ET AL | $379.67K | 1.16% | 2026-06-30 |
| 11 | SIG BROKERAGE, LP | $194.70K | 0.59% | 2026-06-30 |
| 12 | Walleye Capital LLC | $128.50K | 0.39% | 2026-06-30 |
7 filers$10.64M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $4.12M | 38.76% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $2.94M | 27.67% | 2026-06-30 |
| 3 | Caption Management, LLC | $2.51M | 23.59% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $819.69K | 7.70% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $105.14K | 0.99% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $84.24K | 0.79% | 2026-09-30 |
| 7 | Walleye Capital LLC | $52.57K | 0.49% | 2026-06-30 |
MLTX Insider Trading (Form 4)
Latest: 2026-07-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Kristian Reich | Chief Scientific Officer | Sell (S) | −1,100 | $20.00 | -$22.0K | EDGAR |
| 2026-07-23 | Kristian Reich | Chief Scientific Officer | Sell (S) | −52,448 | $20.02 | -$1.05M | EDGAR |
| 2026-07-21 | Kristian Reich | Chief Scientific Officer | Sell (S) | −43,700 | $20.09 | -$877.9K | EDGAR |
| 2026-07-20 | Kristian Reich | Chief Scientific Officer | Sell (S) | −16,105 | $20.01 | -$322.3K | EDGAR |
| 2026-07-13 | da Silva Jorge Santos | Chief Executive Officer | Sell (S) | −102,225 | $20.02 | -$2.05M | EDGAR |
| 2026-07-02 | da Silva Jorge Santos | Chief Executive Officer | Sell (S) | −47,775 | $20.03 | -$956.9K | EDGAR |
| 2026-06-23 | Matthias Bodenstedt | Chief Financial Officer | Sell (S) | −39,120 | $22.04 | -$862.2K | EDGAR |
| 2026-06-22 | BVF INC/IL | Director | Award (A) | — | — | EDGAR | |
| 2026-06-18 | Catherine Moukheibir | Director | Grant (A) | +22,195 opt | — | EDGAR | |
| 2026-06-18 | Ramnik Xavier | Director | Grant (A) | +22,195 opt | — | EDGAR | |
| 2026-06-18 | Matthias Bodenstedt | Chief Financial Officer | Sell (S) | −17,876 | $19.67 | -$351.6K | EDGAR |
| 2026-06-18 | Spike Loy | Director | Grant (A) | +22,195 opt | — | EDGAR | |
| 2026-06-18 | Andrew John Phillips | Director | Grant (A) | +22,195 opt | — | EDGAR | |
| 2026-06-17 | Kristian Reich | Chief Scientific Officer | Sell (S) | −150,000 | $19.01 | -$2.85M | EDGAR |
| 2026-05-13 | Matthias Bodenstedt | Chief Financial Officer | Sell (S) | −13,653 | $20.02 | -$273.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MLTX Insider Holdings
8 insiders · @ $12.71
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | Director | 8,302,735 | $105.49M | $0 | 1 | 2026-06-22 |
| 2 | Bihua Chen | 10%+ Owner | 8,190,943 | $104.07M | $62.47M | 6 | 2025-10-01 |
| 3 | BIOTECHNOLOGY VALUE FUND II LP | Director | 8,168,838 | $103.79M | $0 | 1 | 2025-06-09 |
| 4 | da Silva Jorge Santos | Chief Executive Officer | 2,843,182 | $36.12M | -$19.15M | 11 | 2026-07-13 |
| 5 | Kristian Reich | Chief Scientific Officer | 2,746,587 | $34.90M | -$19.54M | 16 | 2026-07-29 |
| 6 | Matthias Bodenstedt | Chief Financial Officer | 1,115,435 | $14.17M | -$9.02M | 12 | 2026-06-23 |
| 7 | BIOTECHNOLOGY VALUE FUND L P | Director | 1,039,238 | $13.20M | -$162.97M | 2 | 2026-04-02 |
| 8 | Simon Sturge | Director | 171,980 | $2.19M | -$9.19M | 6 | 2025-06-09 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MLTX Board & Officers
As of SEC filings through Jul 29, 2026Directors 15
- Andrew John Phillips · since Apr 5, 2022
- Biotechnology Value Fund II LP (entity) · since Apr 5, 2022
- Biotechnology Value Fund L P (entity) · since Apr 5, 2022
- Bvf Gp Holdings LLC (entity) · since Apr 5, 2022
- Bvf I Gp LLC (entity) · since Apr 5, 2022
- Bvf II Gp LLC (entity) · since Apr 5, 2022
- Bvf Inc/il (entity) · since Apr 5, 2022
- Bvf Partners L P/il (entity) · since Apr 5, 2022
- Catherine Moukheibir · since Apr 5, 2022
- Mark N Lampert · since Apr 5, 2022
- Ramnik Xavier · since Apr 5, 2022
- Spike Loy · since Apr 5, 2022
- da Silva Jorge Santos · since Apr 5, 2022
- BVF Partners OS Ltd. (entity) · listed since Jun 2023
- Biotechnology Value Trading Fund OS LP (entity) · listed since Jun 2023
Officers 3
- da Silva Jorge Santos · Chief Executive Officer · since Apr 5, 2022
- Matthias Bodenstedt · Chief Financial Officer · since Apr 5, 2022
- Kristian Reich · Chief Scientific Officer · since Apr 5, 2022
10% owners 8
- Biotechnology Value Fund II LP (entity) · since Apr 5, 2022
- Biotechnology Value Fund L P (entity) · since Apr 5, 2022
- Bvf Gp Holdings LLC (entity) · since Apr 5, 2022
- Bvf I Gp LLC (entity) · since Apr 5, 2022
- Bvf II Gp LLC (entity) · since Apr 5, 2022
- Bvf Inc/il (entity) · since Apr 5, 2022
- Bvf Partners L P/il (entity) · since Apr 5, 2022
- Mark N Lampert · since Apr 5, 2022
Changes in the last 10 years (53)
| Feb 18, 2026 | The company announced the departure of Simon Sturge from the board in an SEC filing |
| Oct 1, 2025 | Cormorant Private Healthcare Fund IV LP reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2025 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2025 | Cormorant Private Healthcare Fund II, LP reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2025 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2025 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2025 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Oct 4, 2023 | Cormorant Private Healthcare Fund IV LP first on file as a 10% owner |
| Oct 4, 2023 | Cormorant Private Healthcare Fund III LP first on file as a 10% owner |
| Oct 4, 2023 | Cormorant Private Healthcare Fund II, LP first on file as a 10% owner |
| Oct 4, 2023 | Cormorant Global Healthcare Master Fund, LP first on file as a 10% owner |
| Oct 4, 2023 | Cormorant Asset Management, LP first on file as a 10% owner |
| Jun 12, 2023 | Biotechnology Value Trading Fund OS LP first listed as a director in an SEC filing |
| Jun 12, 2023 | BVF Partners OS Ltd. first listed as a director in an SEC filing |
| Apr 7, 2022 | Helix Holdings LLC reported in an SEC filing no longer being a director |
| Apr 7, 2022 | Helix Holdings LLC reported in an SEC filing no longer being a 10% owner |
| Apr 7, 2022 | Bihua Chen no longer listed as a director in SEC filings |
| Apr 7, 2022 | Bihua Chen no longer listed as CEO and Chairman in SEC filings |
| Apr 5, 2022 | da Silva Jorge Santos became a director |
| Apr 5, 2022 | da Silva Jorge Santos became Chief Executive Officer |
| Apr 5, 2022 | Spike Loy became a director |
| Apr 5, 2022 | Simon Sturge became a director |
| Apr 5, 2022 | Ramnik Xavier became a director |
| Apr 5, 2022 | Matthias Bodenstedt became Chief Financial Officer |
| Apr 5, 2022 | Mark N Lampert became a director |
| Apr 5, 2022 | Mark N Lampert became a 10% owner |
| Apr 5, 2022 | Kristian Reich became Chief Scientific Officer |
| Apr 5, 2022 | Kara Lassen became a director |
| Apr 5, 2022 | Catherine Moukheibir became a director |
| Apr 5, 2022 | Bvf Partners L P/il became a director |
| Apr 5, 2022 | Bvf Partners L P/il became a 10% owner |
| Apr 5, 2022 | Bvf Inc/il became a director |
| Apr 5, 2022 | Bvf Inc/il became a 10% owner |
| Apr 5, 2022 | Bvf II Gp LLC became a director |
| Apr 5, 2022 | Bvf II Gp LLC became a 10% owner |
| Apr 5, 2022 | Bvf I Gp LLC became a director |
| Apr 5, 2022 | Bvf I Gp LLC became a 10% owner |
| Apr 5, 2022 | Bvf Gp Holdings LLC became a director |
| Apr 5, 2022 | Bvf Gp Holdings LLC became a 10% owner |
| Apr 5, 2022 | Biotechnology Value Fund L P became a director |
| Apr 5, 2022 | Biotechnology Value Fund L P became a 10% owner |
| Apr 5, 2022 | Biotechnology Value Fund II LP became a director |
| Apr 5, 2022 | Biotechnology Value Fund II LP became a 10% owner |
| Apr 5, 2022 | Andrew John Phillips became a director |
| Oct 19, 2020 | Will Lewis became a director |
| Oct 19, 2020 | Nancy T Chang became a director |
| Oct 19, 2020 | John P. Schmid became a director |
| Oct 19, 2020 | Jay Scollins became Chief Financial Officer |
| Oct 19, 2020 | Helix Holdings LLC became a director |
| Oct 19, 2020 | Helix Holdings LLC became a 10% owner |
| Oct 19, 2020 | Bihua Chen became a director |
| Oct 19, 2020 | Bihua Chen became a 10% owner |
| Oct 19, 2020 | Bihua Chen became CEO and Chairman |
Not reported recently (5)
- Kara Lassen · Last reported as a director in an SEC filing dated Apr 13, 2023
- Will Lewis · Last reported as a director in an SEC filing dated Oct 19, 2020
- Nancy T Chang · Last reported as a director in an SEC filing dated Oct 19, 2020
- John P. Schmid · Last reported as a director in an SEC filing dated Oct 19, 2020
- Jay Scollins · Last reported as Chief Financial Officer in an SEC filing dated Oct 19, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MLTX Proposed Insider Sales (Form 144)
Latest: 2026-07-15
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-15 | Reich Kristian | Officer | 150,000 | $2.92M | 2026-07-15 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-06-30 | Santos da Silva Jorge | Officer, CEO | 150,000 | $3.00M | 2026-06-30 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-06-15 | Reich Kristian | Officer | 150,000 | $2.85M | 2026-06-15 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-04-10 | Jorge Pedro Santos Radeck D Silva | CEO | 150,000 | $2.79M | 2026-04-10 | UBS Financial Services Inc | — | EDGAR |
| 2026-04-09 | Bodenstedt Matthias | Officer, CFO | 160,870 | $2.97M | 2026-04-09 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-03-31 | BVF PARTNERS L P/IL | 10% Stockholder, Affiliate of Director | 3,750,000 | $63.49M | 2026-03-31 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2025-12-08 | Jorge Pedro Santos Radeck Da Silva | Officer, Director, CEO | 200,000 | $2.98M | 2025-12-08 | UBS Financial Services Inc | — | EDGAR |
| 2025-12-08 | Kristian Dieter Johannes Reich | Officer, Director, Chief Scientific Officer | 202,908 | $3.00M | 2025-12-08 | UBS Financial Services Inc | — | EDGAR |
| 2025-07-03 | Moukheibir Catherine | Director | 23,500 | $1.15M | 2025-07-03 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-02-15 | Santos da Silva Jorge | CEO | 200,000 | $12.79M | 2024-02-15 | UBS Financial Services Inc | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-04 | Earnings results | EDGAR |
| 2026-09-30 | Other events | EDGAR |
| 2026-08-10 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-07-15 | Other events | EDGAR |
| 2026-06-25 | Material agreement | EDGAR |
| 2026-06-22 | Regulation FD disclosure · Other events | EDGAR |
| 2026-06-09 | Director or officer change · Shareholder vote results | EDGAR |
| 2026-06-01 | Material agreement | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
14 ETFs hold MLTX
14 shown · $8.55M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | TCAF T. Rowe Price Capital Appreciation Equity ETF | Nport | 0.04% | $3.3M | — | 2026-06-30 |
| 2 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.6M | — | 2026-09-30 |
| 3 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.04% | $986,069 | $2.7B | 2026-11-06 |
| 4 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.05% | $629,449 | — | 2026-07-31 |
| 5 | OPTZ Optimize Strategy Index ETF | Nport | 0.17% | $473,802 | — | 2026-06-30 |
| 6 | GWX State Street® SPDR® S&P® International Small Cap ETF | SPDR (State Street) | 0.05% | $417,695 | $896.1M | 2026-11-05 |
| 7 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $336,884 | $10.0B | 2026-11-05 |
| 8 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.66% | $306,657 | — | 2026-07-31 |
| 9 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $243,367 | $4.0B | 2026-11-05 |
| 10 | TMED T. Rowe Price Health Care ETF | Nport | 0.66% | $152,314 | — | 2026-06-30 |
| 11 | SGRW Harbor Active Small Cap Growth ETF | Nport | 0.31% | $82,777 | — | 2026-07-31 |
| 12 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.01% | $36,908 | $656.6M | 2026-11-06 |
| 13 | MSML iShares MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.01% | $21,688 | $271.8M | 2026-11-06 |
| 14 | TNXT T. Rowe Price Innovation Leaders ETF | Nport | 0.09% | $16,764 | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.80
TTM Revenue
—
TTM Net Income
$-262.22M
TTM Op. Cash Flow
$-225.18M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-61.80M | $-0.84 | $-55.56M |
| Q1 '26 | 2026-03-31 | — | $-69.71M | $-0.98 | $-66.29M |
| Q4 '25 | 2025-12-31 | — | $-60.02M | $-0.92 | $-58.79M |
| Q3 '25 | 2025-09-30 | — | $-70.69M | $-1.10 | $-44.54M |
| Q2 '25 | 2025-06-30 | — | $-55.22M | $-0.87 | $-54.53M |
| Q1 '25 | 2025-03-31 | — | $-39.94M | $-0.63 | $-38.14M |
| Q4 '24 | 2024-12-31 | — | $-44.09M | $-0.72 | $-48.47M |
| Q3 '24 | 2024-09-30 | — | $-36.11M | $-0.56 | $-25.28M |
| Q2 '24 | 2024-06-30 | — | $-24.27M | $-0.39 | $-27.89M |
| Q1 '24 | 2024-03-31 | — | $-13.67M | $-0.22 | $-14.95M |
| Q4 '23 | 2023-12-31 | — | $-7.44M | $-0.10 | $-12.34M |
| Q3 '23 | 2023-09-30 | — | $-9.43M | $-0.18 | $-9.25M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.05
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-61.2%
ROA
-45.7%
Div Yield
0.00%
FCF Yield
-25.69%
Debt/Equity
0.23
Current Ratio
—
Market Cap
$876.59M
as of 2026-11-09
MLTX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $353.2B | 30.0 | +9.7% | +18.3% | 44 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.5% | 56 |
| ISRG Intuitive Surgical Inc. | $160.0B | 55.8 | +20.5% | −17.9% | 18 |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.9B | 7.9 | +56.2% | −60.8% | 49 |
| PODD Insulet Corporation | $10.2B | 28.1 | +29.4% | −47.0% | 33 |
| DYN Dyne Therapeutics, Inc. Common Stock | $3.4B | — | — | +1.5% | 86 |
| IMNM Immunome, Inc. | $2.2B | — | — | −5.7% | 76 |
| MLTX MoonLake Immunotherapeutics Class A Ordi | $981M | — | — | +6.3% | 40 |
| Peer median | $90.4B | 30.0 | +24.9% | −2.1% | 47 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.83M
SI % of Float
14.35%
Days to Cover
4.08
Short Vol Ratio
23.0%
Free Float
54.60M
Float %
64.2%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14